Alzamend Neuro Aktie [WKN DE: A3CSHQ / ISIN: US02262M3088]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Alzamend Neuro Inc Registered Shs

13:30		EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 (Benzinga)
19.02.25		EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels (Benzinga)
19.11.24		EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
16.10.24		EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
20.08.24		Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
19.08.24		Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details (Benzinga)
05.08.24		EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
22.05.24		Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Businesswire)
14.05.24		Alzamend Neuro Announces Initial Closing of Private Placement (Businesswire)
09.05.24		Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Businesswire)
09.05.24		EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga)
07.05.24		Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide (Benzinga)
07.05.24		Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Businesswire)
24.04.24		Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying (Benzinga)
11.12.23		Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Businesswire)
20.11.23		Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Businesswire)
16.11.23		Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement (Businesswire)
13.11.23		Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001 (Businesswire)
30.10.23		Alzamend Neuro Announces Reverse Stock Split (Businesswire)
23.10.23		Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001 (Businesswire)
02.10.23		Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Businesswire)
22.09.23		Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Businesswire)
30.08.23		Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Businesswire)
22.06.23		Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Businesswire)
13.06.23		Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference (Businesswire)
03.04.23		Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type (Businesswire)
22.03.23		Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
16.03.23		Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Businesswire)
26.01.23		Alzamend Neuro to Present at Sequire Biotechnology Conference (Businesswire)
04.01.23		Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Businesswire)
15.11.22		Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Businesswire)
05.10.22		Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects (Businesswire)
29.09.22		Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type (Businesswire)
22.09.22		Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Businesswire)
18.07.22		Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Businesswire)
03.06.22		Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Businesswire)
17.05.22		Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Businesswire)
05.05.22		Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
28.04.22		Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
11.04.22		Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s (Businesswire)
04.04.22		Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board (Businesswire)
20.12.21		Top Biotech IPOs Of 2021 That Soared As Much As 500% (RTTNews)
15.12.21		Pre-market Movers: IDRA, GRTX, SEAC, ALZN, SIDU… (RTTNews)
14.12.21		Pre-market Movers: XCUR, MIND, NES, APTO, ALZN… (RTTNews)
19.11.21		Pre-market Movers: TUSK, AQB, LGVN, CNTB, UWMC… (RTTNews)
11.11.21		Pre-market Movers: FOSL, AFRM, RWLK, BYND, CRCT… (RTTNews)
23.06.21		Pre-market Movers: ACST, TENX, GMTX, EYES… (RTTNews)

Newssuche

Meistgelesene Nachrichten

Bitcoin Kurs Prognose: Absturz auf 90.000 US-Dollar bereits diese Woche?

EQS-CMS: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Release of a capital market information

Trump stellt erneut US-Rolle bei Vereinten Nationen infrage

ams-OSRAM-Aktie schächelt: ams-OSRAM erhält EU-Freigabe für staatliche Förderung aus Österreich

Investieren in die Zukunft: Diese 5 Quantencomputing-Aktien sind vielversprechend

Bundestagswahl in Deutschland: Union laut Hochrechnungen klar vorn, FDP scheitert an Fünf-Prozent-Hürde - SPD verliert deutlich

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.02.2025 23:14
Kaufwert:	EUR
	Hinzufügen Speichern